← boardnext 2026-07-23next 2026-07-31next 2026-07-31next 2026-08next 2026-11next 2027-06next 2027-06next 2027-06next 2027-11next 2027-12next 2028-02next 2028-03next 2028-06next 2028-09next 2029-04next 2030-02next 2030-05next 2030-10
BNTX
BioNTech SEdistress 1/10 · well-funded / low risk$91.35-1%today-23% from 52w high
Oncology 3Infectious Disease 1Respiratory 1
Lead: COVID-19 · target PD-1
Revenue
$118M
Liquidity
$16919M
Runway
—
Shares 1y
0%
Price & events
-22.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
-0.2%
1W
+0.8%
1M
-13.5%
3M
-21.2%
6M
-20.3%
1Y
+6.8%
2Y
-67.2%
5Y
+8.0%
All
Overview
- Market Cap
- $23.10B
- Enterprise Value
- $13.23B
- Volume
- 31.08K
- 52 Week Range
- $83.89 – $119
- Total Shares
- 252.88M
- Float Shares
- 110.10M
- Short %
- 3.40%
- % Held by Insiders
- 57.13%
- % Held by Institutions
- 20.48%
- RVOL
- 0.03x
- Beta
- 1.32
Pipeline stages · 22 programs
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (origin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT162b2 (2025/2026 formulation)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT162b2 Vaccine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
PM8002, Nab-Paclitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
RO7198457 intravenous (IV)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT314, Pumitamig, SoC chemotherapy treatment 1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT166a
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT3212, Pumitamig
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Show all 22 programs · 12 more ▾
BNT326, BNT327, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT323, BNT327
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT317 DL1, BNT317 DL2, BNT317 DL3
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT324, Docetaxel, Prednisone/prednisolone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT113, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT116, Cemiplimab, Docetaxel
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT329, CA19-9-targeting monoclonal antibody
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT3214
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT142
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Investigational Influenza Vaccine, COVID-19 Vaccine, Licensed Influenza Vaccine 1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT165e
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
NEO-PTC-01, IL-2, PD-1 InhibitorsPD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 37 trials · 33 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07-23 Estimated 50% readout ~2026-10-06 final ~2026-11-30 | Phase 3 | Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (origin | SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19 | — | active not recruiting |
| 2026-07-31 Estimated 50% readout ~2026-10-14 | Phase 3 | BNT162b2 (2025/2026 formulation) | COVID-19, SARS-COV-2 Infection | — | active not recruiting |
| 2026-07-31 Estimated 50% readout ~2026-10-14 | Phase 3 | BNT162b2 Vaccine | COVID-19, SARS-COV-2 Infection | — | active not recruiting |
| 2026-08 Estimated 50% readout ~2026-09-15 | Phase 2 | PM8002, Chemotherapy Regimen 1, Chemotherapy Regimen 2 | CRC (Colorectal Cancer) | 40 | not yet recruiting |
| 2026-10 Estimated 50% readout ~2026-11-15 | Phase 1/2 | PM8002, PM1009, atezolizumab | HCC, Liver Cancer | — | not yet recruiting |
Show all 37 trials · 32 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10-30 Estimated 50% readout ~2026-12-14 | Phase 1/2 | PM8002, nab-paclitaxel | TNBC | — | active not recruiting |
| 2026-11 Estimated 50% readout ~2026-12-16 | Phase 2 | RO7198457 intravenous (IV) | Colorectal Cancer Stage II, Colorectal Cancer Stage III | — | active not recruiting |
| 2027-01-01 Estimated 50% readout ~2027-02-15 | Phase 2 | PM8002, FOLFIRI | Neuroendocrine Neoplasm | — | recruiting |
| 2027-01-25 Estimated 50% readout ~2027-04-10 | Phase 3 | PM8002, Paclitaxel, Topotecan | SCLC | — | active not recruiting |
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | BNT166a | Mpox (Monkeypox), Smallpox, Orthopoxvirus Infection | — | recruiting |
| 2027-06 Estimated 50% readout ~2027-07-01 | Phase 1 | BNT314 | Advanced Malignant Solid Tumor | — | active not recruiting |
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide | Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer | — | active not recruiting |
| 2027-07 Estimated 50% readout ~2027-09-14 | Phase 3 | PM8002, Nab-Paclitaxel | Triple Negative Breast Cancer(TNBC) | — | recruiting |
| 2027-11 Estimated 50% readout ~2027-12-16 | Phase 1/2 | BNT3212, Pumitamig | Advanced Solid Tumor | — | recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | Pumitamig, Nab-paclitaxel, Gemcitabine | Pancreatic Ductal Adenocarcinoma (PDAC) | — | recruiting |
| 2028-01 Estimated 50% readout ~2028-02-15 | Phase 2 | Pumitamig, Bevacizumab, Temozolomide | Recurrent Glioblastoma | — | recruiting |
| 2028-02 Estimated 50% readout ~2028-03-17 | Phase 1/2 | BNT326, Pumitamig, Itraconazole | Advanced Solid Tumor | — | recruiting |
| 2028-03 Estimated 50% readout ~2028-05-15 | Phase 3 | BNT323/DB-1303, Doxorubicin, Paclitaxel | Endometrial Cancer | — | recruiting |
| 2028-06 Estimated 50% readout ~2028-07-01 | Phase 1 | BNT317 DL1, BNT317 DL2, BNT317 DL3 | Advanced Solid Tumor | — | recruiting |
| 2028-08 Estimated 50% readout ~2028-09-15 | Phase 2 | BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel | Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers | — | active not recruiting |
| 2028-09 Estimated 50% readout ~2028-10-16 | Phase 1/2 | BNT324, BNT327 | Advanced Lung Cancer | — | recruiting |
| 2028-10 Estimated 50% readout ~2028-11-15 | Phase 2 | Pumitamig, Docetaxel | Non-small Cell Lung Cancer | — | recruiting |
| 2028-12 Estimated 50% readout ~2029-02-14 | Phase 3 | Pumitamig, Atezolizumab, Etoposide | Extensive-stage Small-cell Lung Cancer | — | recruiting |
| 2029-01 Estimated 50% readout ~2029-02-15 | Phase 1/2 | BNT326, BNT327, Pembrolizumab | Non-small Cell Lung Cancer | — | recruiting |
| 2029-02 Estimated 50% readout ~2029-04-17 | Phase 2/3 | Pumitamig, Pembrolizumab, Carboplatin | Non-small Cell Lung Cancer | — | recruiting |
| 2029-04 Estimated 50% readout ~2029-06-15 | Phase 2/3 | BNT113, Pembrolizumab | Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer | — | recruiting |
| 2029-08 Estimated 50% readout ~2029-09-15 | Phase 1/2 | BNT323, BNT327 | Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer | — | recruiting |
| 2029-12 Estimated 50% readout ~2030-02-14 | Phase 3 | Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine | Breast Neoplasms | — | recruiting |
| 2030-02 Estimated 50% readout ~2030-03-03 | Phase 1 | BNT116, Cemiplimab, Docetaxel | Non-Small Cell Lung Cancer | — | recruiting |
| 2030-05 Estimated 50% readout ~2030-06-15 | Phase 1/2 | BNT329, CA19-9-targeting monoclonal antibody | Advanced Solid Cancers | — | recruiting |
| 2030-10 Estimated 50% readout ~2030-11-15 | Phase 1/2 | BNT3214 | Advanced Solid Tumor Cancer | — | recruiting |
| 2030-12 Estimated 50% readout ~2031-01-15 | Phase 1/2 | BNT314, Pumitamig, SoC chemotherapy treatment 1 | Metastatic Colorectal Cancer | — | recruiting |
| 2031-02 Estimated 50% readout ~2031-04-17 | Phase 3 | BNT324, Docetaxel, Prednisone/prednisolone | Metastatic Castration-resistant Prostate Cancer | — | recruiting |
| 2025-12-22 | Phase 1/2 | BNT142 | Solid Tumor | 73 | terminated |
| 2025-07-15 | Phase 1/2 | Investigational Influenza Vaccine, COVID-19 Vaccine, Licensed Influenza Vaccine 1 | Influenza,Human, COVID-19 | 1353 | completed |
| 2025-05-28 | Phase 1/2 | BNT165e | Malaria | 163 | completed |
| 2025-03-26 | Phase 1 | NEO-PTC-01, IL-2, PD-1 Inhibitors | Unresectable Melanoma, Metastatic Melanoma | 22 | terminated |
Catalyst news & presentations · 1
- 2026-08-04Confirmed 100%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $122 (+33% upside) · 20 analysts
- 2026-07-08Morgan StanleyOverweight
- 2026-05-27UBSNeutral → Buy
- 2026-05-22BernsteinMarket Perform
- 2026-05-06Canaccord GenuityBuy
- 2026-05-06Wells FargoOverweight
- 2026-04-27HC Wainwright & Co.Buy
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-23The BioNTech Omicron BA.4/ BA.5 Booster - BioNTech SE bets on updated protection - Ad-hoc-news.de
- 2026-07-22BioNTech SE (0A3M) Q1 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21BioNTech: The Market Is Paying Too Much For An Unproven Pipeline (NASDAQ:BNTX) - Seeking Alpha
- 2026-07-21BioNTech to report Q2 2026 financial results on August 4 - scanx.trade
- 2026-07-21BioNTech to report Q2 2026 financial results an... - Pluang
- 2026-07-21BioNTech to release Q2 2026 results and host in... - Pluang
- 2026-07-21BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026 - The Manila Times
- 2026-07-21BioNTech to Report Second Quarter 2026 Financial Results on August 4, 2026 - Moomoo
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.